ECSP22009803A - [1,2,4]triazolo[1,5-c]quinazolin-5-aminas - Google Patents
[1,2,4]triazolo[1,5-c]quinazolin-5-aminasInfo
- Publication number
- ECSP22009803A ECSP22009803A ECSENADI20229803A ECDI202209803A ECSP22009803A EC SP22009803 A ECSP22009803 A EC SP22009803A EC SENADI20229803 A ECSENADI20229803 A EC SENADI20229803A EC DI202209803 A ECDI202209803 A EC DI202209803A EC SP22009803 A ECSP22009803 A EC SP22009803A
- Authority
- EC
- Ecuador
- Prior art keywords
- compounds
- quinazolin
- triazolo
- preparation
- pharmaceutical compositions
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- OEBXVPQOMXLUJF-UHFFFAOYSA-N [1,2,4]triazolo[1,5-c]quinazolin-5-amine Chemical class C1=CC=C2C3=NC=NN3C(=N)NC2=C1 OEBXVPQOMXLUJF-UHFFFAOYSA-N 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000002074 deregulated effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención comprende compuestos de [1,2,4]triazolo[1,5-c]quinazolin-5-amina de la fórmula general (I): (conforme a figura constante en resumen de memoria técnica) en donde R1, R2, R3, R4, R5, R6, R7 y R8 son como se definen en la presente, métodos para la preparación de dichos compuestos, compuestos intermedios útiles para la preparación de dichos compuestos, composiciones farmacéuticas y combinaciones que comprenden dichos compuestos y el uso de dichos compuestos para la elaboración de composiciones farmacéuticas para el tratamiento o la profilaxis de enfermedades, en especial de cáncer o afecciones con respuestas inmunes desreguladas u otros trastornos asociados con la señalización anormal de AHR, como un único agente o en combinación con otros ingredientes activos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19191299 | 2019-08-12 | ||
| EP20167707 | 2020-04-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP22009803A true ECSP22009803A (es) | 2022-03-31 |
Family
ID=72243077
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI20229803A ECSP22009803A (es) | 2019-08-12 | 2022-02-08 | [1,2,4]triazolo[1,5-c]quinazolin-5-aminas |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20230113037A1 (es) |
| EP (1) | EP4013508A1 (es) |
| JP (1) | JP2022544952A (es) |
| KR (1) | KR20220045978A (es) |
| CN (1) | CN114466850B (es) |
| AU (1) | AU2020328154A1 (es) |
| BR (1) | BR112022001628A2 (es) |
| CA (1) | CA3150544A1 (es) |
| CO (1) | CO2022001257A2 (es) |
| CR (1) | CR20220064A (es) |
| DO (1) | DOP2022000031A (es) |
| EC (1) | ECSP22009803A (es) |
| GE (1) | GEP20247611B (es) |
| IL (1) | IL290445A (es) |
| JO (1) | JOP20220034A1 (es) |
| MX (1) | MX2022001803A (es) |
| PE (1) | PE20220967A1 (es) |
| PH (1) | PH12022550353A1 (es) |
| TW (1) | TWI865582B (es) |
| WO (1) | WO2021028382A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3180670A1 (en) | 2020-04-24 | 2021-10-28 | Bayer Aktiengesellschaft | Substituted aminothiazoles as dgkzeta inhibitors for immune activation |
| WO2022049253A1 (en) * | 2020-09-07 | 2022-03-10 | Bayer Aktiengesellschaft | Substituted n-heteroaryl-n-pyridinylacetamides as p2x4 modulators |
| CN114181212B (zh) * | 2020-09-15 | 2023-06-06 | 山东轩竹医药科技有限公司 | 哒嗪酮类AhR抑制剂 |
| CN114621236B (zh) * | 2022-04-25 | 2024-06-18 | 河南湾流生物科技有限公司 | 一种喹啉类饲料添加剂的制备方法 |
| WO2024208198A1 (zh) * | 2023-04-06 | 2024-10-10 | 微境生物医药科技(上海)有限公司 | 作为DGKζ抑制剂的噻唑类化合物 |
| WO2024242495A1 (ko) * | 2023-05-25 | 2024-11-28 | 주식회사 매직불릿테라퓨틱스 | 단백질 키나아제 억제용 신규 화합물 및 이를 포함하는 약학조성물 |
| WO2025011623A1 (zh) * | 2023-07-12 | 2025-01-16 | 上海壹迪生物技术有限公司 | 氰基喹啉类靶向蛋白降解分子、其制备方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6358964B1 (en) * | 2000-07-26 | 2002-03-19 | King Pharmaceuticals Research And Development, Inc. | Adenosine, A3 receptor modulators |
| CA2586420A1 (en) * | 2004-11-22 | 2007-04-12 | King Pharmaceuticals Research & Development, Inc. | Enhancing treatment of cancer and hif-1 mediated disoders with adenosine a3 receptor antagonists |
| PE20100362A1 (es) | 2008-10-30 | 2010-05-27 | Irm Llc | Derivados de purina que expanden las celulas madre hematopoyeticas |
| EP2598138B1 (en) | 2010-07-27 | 2020-05-06 | Trustees of Boston University | Aryl hydrocarbon receptor (ahr) modifiers as novel cancer therapeutics |
| US10457683B2 (en) * | 2017-04-12 | 2019-10-29 | Magenta Therapeutics Inc. | Aryl hydrocarbon receptor antagonists and uses thereof |
| WO2019018562A1 (en) * | 2017-07-19 | 2019-01-24 | Ideaya Biosciences, Inc. | AMIDO COMPOUND AS MODULATORS OF AHR |
| MX2021005662A (es) * | 2018-11-14 | 2021-10-13 | Broad Inst Inc | Compuestos activadores del receptor de aril hidrocarburo (ahr) como agentes terapéuticos para el cáncer. |
-
2020
- 2020-08-10 BR BR112022001628A patent/BR112022001628A2/pt unknown
- 2020-08-10 WO PCT/EP2020/072377 patent/WO2021028382A1/en active Application Filing
- 2020-08-10 PE PE2022000229A patent/PE20220967A1/es unknown
- 2020-08-10 JP JP2022509121A patent/JP2022544952A/ja active Pending
- 2020-08-10 MX MX2022001803A patent/MX2022001803A/es unknown
- 2020-08-10 CR CR20220064A patent/CR20220064A/es unknown
- 2020-08-10 JO JOP/2022/0034A patent/JOP20220034A1/ar unknown
- 2020-08-10 CN CN202080069709.0A patent/CN114466850B/zh active Active
- 2020-08-10 CA CA3150544A patent/CA3150544A1/en active Pending
- 2020-08-10 KR KR1020227007880A patent/KR20220045978A/ko active Pending
- 2020-08-10 US US17/634,930 patent/US20230113037A1/en active Pending
- 2020-08-10 AU AU2020328154A patent/AU2020328154A1/en active Pending
- 2020-08-10 EP EP20761758.0A patent/EP4013508A1/en active Pending
- 2020-08-10 GE GEAP202015897A patent/GEP20247611B/en unknown
- 2020-08-12 TW TW109127401A patent/TWI865582B/zh active
-
2022
- 2022-02-07 DO DO2022000031A patent/DOP2022000031A/es unknown
- 2022-02-08 IL IL290445A patent/IL290445A/en unknown
- 2022-02-08 CO CONC2022/0001257A patent/CO2022001257A2/es unknown
- 2022-02-08 EC ECSENADI20229803A patent/ECSP22009803A/es unknown
- 2022-02-11 PH PH1/2022/550353A patent/PH12022550353A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN114466850A (zh) | 2022-05-10 |
| CO2022001257A2 (es) | 2022-03-08 |
| TW202126655A (zh) | 2021-07-16 |
| IL290445A (en) | 2022-04-01 |
| WO2021028382A1 (en) | 2021-02-18 |
| US20230113037A1 (en) | 2023-04-13 |
| KR20220045978A (ko) | 2022-04-13 |
| GEP20247611B (en) | 2024-03-11 |
| PH12022550353A1 (en) | 2023-01-23 |
| CN114466850B (zh) | 2024-09-10 |
| DOP2022000031A (es) | 2022-03-15 |
| TWI865582B (zh) | 2024-12-11 |
| EP4013508A1 (en) | 2022-06-22 |
| MX2022001803A (es) | 2022-03-11 |
| CR20220064A (es) | 2022-05-04 |
| CA3150544A1 (en) | 2021-02-18 |
| PE20220967A1 (es) | 2022-06-10 |
| JOP20220034A1 (ar) | 2023-01-30 |
| AU2020328154A1 (en) | 2022-03-03 |
| BR112022001628A2 (pt) | 2022-06-21 |
| JP2022544952A (ja) | 2022-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP22009803A (es) | [1,2,4]triazolo[1,5-c]quinazolin-5-aminas | |
| CO2019008684A2 (es) | 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas para el tratamiento del cancer | |
| ECSP22041839A (es) | Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activación inmune | |
| CL2023002090A1 (es) | Inhibidores de kras tricíclicos fusionados | |
| ECSP19030002A (es) | 1,2,4-triazolonas 2,4,5-trisustituidas | |
| CO2018012654A2 (es) | 3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas | |
| CO2022014876A2 (es) | Aminotiazoles sustituidos como inhibidores de dgkzeta para la activación inmune | |
| ECSP034916A (es) | Oxazolidinonas substituidas para terapia de combinacion | |
| MX2023004920A (es) | Compuestos inhibidores de la proteina 6 del linfoma de linfocitos b (bcl6). | |
| ECSP23077322A (es) | Derivados de fósforo como nuevos inhibidores de sos1 | |
| UY37149A (es) | 2–amino–n–[7–metoxi–2,3–dihidroimidazo–[1,2–c]quinazolin–5–il]pirimidin–5–carboxamidas | |
| UY37971A (es) | Derivados de indol macrocíclicos sustituidos | |
| UY37972A (es) | Derivados de indol macrocíclicos sustituidos con cloro | |
| UY38816A (es) | Nuevos derivados de isoquinolina | |
| UY37973A (es) | Derivados de indol macrocíclicos | |
| CL2023002064A1 (es) | Derivados de ácido urólico sintético y métodos de uso de estos | |
| ECSP22093652A (es) | Compuestos de imidazopiridazina y usos de los mismos | |
| MX2022000781A (es) | Triterpenoides sintéticos heteroaromáticos sustituidos polarmente en c17, y métodos de uso de los mismos. | |
| AR126389A1 (es) | Compuestos tricíclicos como inhibidores de kras | |
| AR117459A1 (es) | Imidazopiridina y compuestos de imidazopiridazina y usos de los mismos |